JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.53 -6.61

Buy Sell

Overview

Share price change

24h

Current

Min

3.5

Max

3.82

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+237.6% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-32M 222M
Previous open	10.14
Previous close	3.53

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 lut 2026, 00:00 UTC

Hot Stocks

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 lut 2026, 22:55 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 lut 2026, 21:44 UTC

Earnings

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 lut 2026, 21:39 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 lut 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 lut 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 lut 2026, 23:45 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 lut 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 lut 2026, 22:59 UTC

Acquisitions, Mergers, Takeovers

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 lut 2026, 22:30 UTC

Earnings

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 lut 2026, 22:30 UTC

Earnings

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 lut 2026, 22:21 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 lut 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 lut 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 lut 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4 lut 2026, 21:53 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 lut 2026, 21:51 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 lut 2026, 21:45 UTC

Earnings

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 lut 2026, 21:44 UTC

Earnings

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 lut 2026, 21:43 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 lut 2026, 21:41 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 lut 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 lut 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 lut 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 lut 2026, 21:30 UTC

Earnings

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

237.6% upside

12 Months Forecast

Average 13.2 USD 237.6%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.